Federal grants to Vitalant
Vitalant in Scottsdale, Arizona received $16.3 million in federal grants from fiscal 2021 to 2025, across 13 awards. Its largest program was Cardiovascular Diseases Research, with $6.5 million. In fiscal 2025 it was awarded $3.2 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$16.3 million
- Awards13
- Awarded in FY 2025$3.2 million
- Largest award$4.5 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $1.4 million |
| FY 2022 | 5 | $2.4 million |
| FY 2023 | 4 | $2.3 million |
| FY 2024 | 7 | $7.0 million |
| FY 2025 | 8 | $3.2 million |
Programs that fund Vitalant
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 8 | $6.5 million |
| Allergy and Infectious Diseases Research | 4 | $5.3 million |
| Emerging Infections Programs | 1 | $4.5 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 13 | $16.3 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| RFA-IP-24-046: nationwide cohort of blood donors to estimate burden of respiratory viruses and immunologic response | Emerging Infections Programs | August 29, 2024 | $4.5 million |
| Hematopoietic and immune development in the human chorion - project summary/abstract: hematopoiesis occurs at multiple sites during human prenatal development. In addition to the primary intraembryonic hematopoietic tissues, it is now recognized that the extra-embryonic tissues – the placenta and ch | Allergy and Infectious Diseases Research | April 11, 2022 | $2.7 million |
| Transfusion-related immunomodulation influences infectious disease outcomes | Cardiovascular Diseases Research | June 28, 2021 | $1.9 million |
| Modulation of GALECTIN-9 to target HIV persistence - project summary while the advent of antiretroviral therapy (ART) has dramatically reduced the morbidity and mortality associated with HIV infection, viral eradication is not achievable due to the persistence of latently-infected cells during treat | Allergy and Infectious Diseases Research | July 31, 2024 | $1.6 million |
| The impact of illness and medical treatments on the alloantibody response to platelet transfusion | Cardiovascular Diseases Research | June 25, 2021 | $1.5 million |
| Innate sensing of cell-free dna and the interferon-mediated control of HIV in vivo - project summary while the advent of antiretroviral therapy (ART) has dramatically reduced the morbidity and mortality associated with HIV infection, a cure is not achieved due to the persistence of latently-infected | Allergy and Infectious Diseases Research | March 27, 2023 | $1.1 million |
| Extracellular vesicles as biomarkers and therapeutic targets for atherosclerotic cardiovascular disease in persons living with HIV - project summary: despite antiretroviral therapy (ART), people living with HIV (PLWH) have a two-fold increased risk of cardiovascular disease (CVD) compared with the g | Cardiovascular Diseases Research | May 30, 2024 | $1.1 million |
| Effect of blood donor sex and inter-individual variability in plasma testosterone on the transfusion effectiveness and hemostatic potential of red blood cells and platelets - project summary / abstract the long-term goal of this proposal is to advance transfusion effectiveness and safety by addressi | Cardiovascular Diseases Research | September 24, 2023 | $882,481 |
| Effect of blood donor sex and testosterone on predisposition to hemolysis in stored red blood cells | Cardiovascular Diseases Research | December 31, 2020 | $588,946 |
| Leveraging stored platelet bioenergetics to improve hemostatic function upon transfusion - project summary / abstract the overarching aim of this proposal is to advance the field of personalized transfusion medicine by identifying optimal supplementation and storage procedures to yield platelet prod | Cardiovascular Diseases Research | August 21, 2025 | $375,306 |
Questions people ask
How much federal grant money does Vitalant get?
$16.3 million in 13 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Vitalant the most?
The Department of Health and Human Services, with $16.3 million in 13 awards.
What is Vitalant's largest federal grant?
$4.5 million under Emerging Infections Programs, with its first action in the period on August 29, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Vitalant?
Its largest are Cardiovascular Diseases Research, Allergy and Infectious Diseases Research and Emerging Infections Programs.
Other grant recipients in Scottsdale
- Salt River Pima-Maricopa Indian Community
- Mayo Clinic Arizona
- City of Scottsdale
- Maricopa County Community College District
- Salt River Pima-Maricopa Indian Community
- CND Life Sciences, Inc.
- Sequitur Health Corp.
- Spoc Proteomics Inc.
Largest federal grant recipients in Arizona · Federal grants in Arizona